PulseAugur
EN
LIVE 23:25:55

Stanford expert: Gene-editing therapies not ready for human trials

By PulseAugur Editorial · [1 sources] ·

Gene-editing therapies, particularly for neurological conditions, are not yet mature enough for widespread human trials, according to Stanford University expert Karoly Nikolich. He estimates that it could take up to five years before such treatments are ready for human testing. Nikolich cited two recent cases where patients died following experimental gene-editing treatments, highlighting the need for further research to understand the full-body effects of gene modification. AI

IMPACT AI approaches may accelerate the development timeline for gene-editing therapies, but current safety concerns remain.

RANK_REASON Expert opinion on the readiness of gene-editing therapies for human trials, citing specific cases.

Read on SCMP — Tech →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Stanford expert: Gene-editing therapies not ready for human trials

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Commentary
Expert opinion on the readiness of gene-editing therapies for human trials, citing specific cases.
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
safety, other
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Standard
On-topic for AI-industry coverage; kept in the public index.
Story freshness
55 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. SCMP — Tech TIER_1 English(EN) · Julie Zhang ·

    Gene-editing therapies not yet ready for human trials, Stanford expert says

    Gene-editing therapies for the nervous system may need at least another round of studies before they are safe enough to enter human trials, according to one of the world’s most influential figures in the commercialisation of brain science. “The techniques are reasonably well esta…

RELATED ENTITIES

RELATED TOPICS